Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ER-50891 is a potent retinoic acid receptor alpha (RARα) antagonist. er-50891 reduces the inhibitory effect of allosteric retinoic acid and restores osteoblast differentiation induced by bone morphogenetic protein 2.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 197.00 | |
5 mg | In stock | $ 491.00 | |
10 mg | In stock | $ 578.00 | |
25 mg | In stock | $ 927.00 | |
50 mg | In stock | $ 1,260.00 | |
100 mg | In stock | $ 1,680.00 | |
500 mg | In stock | $ 3,390.00 |
Description | ER-50891 is a potent retinoic acid receptor alpha (RARα) antagonist. er-50891 reduces the inhibitory effect of allosteric retinoic acid and restores osteoblast differentiation induced by bone morphogenetic protein 2. |
In vitro | ER-50891 significantly antagonized the inhibition of ATRA and enhanced the total cell metabolic activity and proliferation of preosteoblasts. Dose-dependent assays show ER-50891 could also rescue ATRA inhibited OCN expression and mineralization with or without the induction of BMP. ER-50891 also suppressed the ALP activity that was synergistically enhanced by BMP and ATRA. Neither ATRA, nor ER-50891 or their combination significantly affected the level of BMP-induced phosphorylated Smad1/5. The antagonist of RARα, ER-50891 could significantly attenuate ATRA's inhibitive effects on BMP 2-induced osteoblastogenesis.[3] |
Molecular Weight | 432.51 |
Formula | C29H24N2O2 |
CAS No. | 187400-85-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 38.7 mg/mL (90.0 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ER 50891 187400-85-7 Metabolism Retinoid Receptor ER50891 ER-50891 inhibitor inhibit